These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 23624993)

  • 21. Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark.
    Madsen AMR; Schaltz-Buchholzer F; Benfield T; Bjerregaard-Andersen M; Dalgaard LS; Dam C; Ditlev SB; Faizi G; Johansen IS; Kofoed PE; Kristensen GS; Loekkegaard ECL; Mogensen CB; Mohamed L; Ostenfeld A; Oedegaard ES; Soerensen MK; Wejse C; Jensen AKG; Nielsen S; Krause TG; Netea MG; Aaby P; Benn CS
    Trials; 2020 Sep; 21(1):799. PubMed ID: 32943115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial.
    Miras AD; Pérez-Pevida B; Aldhwayan M; Kamocka A; McGlone ER; Al-Najim W; Chahal H; Batterham RL; McGowan B; Khan O; Greener V; Ahmed AR; Petrie A; Scholtz S; Bloom SR; Tan TM
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):549-559. PubMed ID: 31174993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
    le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS; Pi-Sunyer X;
    Lancet; 2017 Apr; 389(10077):1399-1409. PubMed ID: 28237263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.
    Jorsal A; Kistorp C; Holmager P; Tougaard RS; Nielsen R; Hänselmann A; Nilsson B; Møller JE; Hjort J; Rasmussen J; Boesgaard TW; Schou M; Videbaek L; Gustafsson I; Flyvbjerg A; Wiggers H; Tarnow L
    Eur J Heart Fail; 2017 Jan; 19(1):69-77. PubMed ID: 27790809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
    Russell-Jones D; Vaag A; Schmitz O; Sethi BK; Lalic N; Antic S; Zdravkovic M; Ravn GM; Simó R;
    Diabetologia; 2009 Oct; 52(10):2046-55. PubMed ID: 19688338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Use of Aspirin to Reduce the Risk of Thrombotic Events in Patients With End-Stage Renal Disease: Protocol for a Randomized Controlled Trial.
    Lemos Cerqueira T; Fartolino Guerrero A; Pérez Fermin CK; Wang R; Balbino EE; Breeze JL; Gonzalez Mego P; Argentina Silva D; Omer WE; Vandevelde NM
    JMIR Res Protoc; 2018 Aug; 7(8):e10516. PubMed ID: 30093367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI).
    Sprung VS; Kemp GJ; Wilding JP; Adams V; Murphy K; Burgess M; Emegbo S; Thomas M; Needham AJ; Weimken A; Schwab RJ; Manuel A; Craig SE; Cuthbertson DJ
    BMJ Open; 2020 Jul; 10(7):e038856. PubMed ID: 32699168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.
    Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Pouwels PJ; Pieters-van den Bos IC; Hoekstra T; Diamant M; van Raalte DH; Cahen DL
    Diabetologia; 2016 Dec; 59(12):2588-2593. PubMed ID: 27627981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial.
    Neeland IJ; Marso SP; Ayers CR; Lewis B; Oslica R; Francis W; Rodder S; Pandey A; Joshi PH
    Lancet Diabetes Endocrinol; 2021 Sep; 9(9):595-605. PubMed ID: 34358471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial.
    Papamargaritis D; Al-Najim W; Lim J; Crane J; Lean M; le Roux C; McGowan B; O'Shea D; Webb D; Wilding J; Davies MJ
    BMJ Open; 2020 Feb; 10(2):e034137. PubMed ID: 32060156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
    Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
    JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simvastatin as a neuroprotective treatment for Parkinson's disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study.
    Carroll CB; Webb D; Stevens KN; Vickery J; Eyre V; Ball S; Wyse R; Webber M; Foggo A; Zajicek J; Whone A; Creanor S
    BMJ Open; 2019 Oct; 9(10):e029740. PubMed ID: 31594876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
    Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
    Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
    Margulies KB; Hernandez AF; Redfield MM; Givertz MM; Oliveira GH; Cole R; Mann DL; Whellan DJ; Kiernan MS; Felker GM; McNulty SE; Anstrom KJ; Shah MR; Braunwald E; Cappola TP;
    JAMA; 2016 Aug; 316(5):500-8. PubMed ID: 27483064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study.
    Terauchi Y; Utsunomiya K; Yasui A; Seki T; Cheng G; Shiki K; Lee J
    Diabetes Ther; 2019 Jun; 10(3):951-963. PubMed ID: 30912033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Moxibustion versus diclofenac sodium gel for the treatment of knee osteoarthritis: a study protocol for a double-blinded, double-placebo, randomised controlled trial.
    Zhou JY; Luo L; Zhu LL; Yin HY; Wu Q; Peng JX; Zhang CS; Lv P; Tang Y; Yu SG
    BMJ Open; 2017 Apr; 7(4):e012879. PubMed ID: 28404609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liraglutide and Renal Outcomes in Type 2 Diabetes.
    Mann JFE; Ørsted DD; Brown-Frandsen K; Marso SP; Poulter NR; Rasmussen S; Tornøe K; Zinman B; Buse JB;
    N Engl J Med; 2017 Aug; 377(9):839-848. PubMed ID: 28854085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of dialysis initiation by a fuzzy mathematics equation (ADIFE): a study protocol for a randomised controlled trial.
    Chen J; Liu Y; Chen X; Sun X; Li W; Yang W; Li P; Sun X; Wang D; Jiang H; Shi W; Liu W; Fu P; Ding X; Chang M; Liu S; Yang X; Cao N; Chen M; Ni Z; Chen J; Sun S; Liang X; Wang H; He Y; Gao B; Wang J; Hao L; Liu J; Li S; He Q; Liu H; Yi N; Shao F; Jiao J; Ma Y; Yao L; Sun Y; Li D; Szczech L; Fang M; Odeh Z; Lin H
    BMJ Open; 2019 Sep; 9(9):e023162. PubMed ID: 31501092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
    Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.